First Clinical Gene Therapy Trial Offers Clues For Muscular Dystrophy

A clinical trial for gene therapy to replace the genetic defect causing the most common form of muscular dystrophy has revealed that some patients mount an immune response to the dystrophin

A clinical trial for gene therapy to replace the genetic defect causing the most common form of muscular dystrophy has revealed that some patients mount an immune response to the dystrophin protein even before they have received the therapy.

Scientists at the University of North Carolina at Chapel Hill School of Medicine found that the immune systems of a number of patients - once thought to be completely devoid of the dystrophin protein - are actually primed by the prior existence of tiny amounts of this important component of muscle.

Immunity to Dystrophin Revealed in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy has revealed a challenge to researchers as an immune reaction to the defective muscle protein, dystrophin, makes it difficult to strenghten patients' muscles.

"These findings are going to be studied intensely going forward, and should help us to understand how to better tailor our treatment approaches to suit the patients' needs," said R. Jude Samulski, professor of pharmacology and director of the Gene Therapy Center at UNC.

Duchenne muscular dystrophy is a genetic disease that causes progressive muscle weakness, and usually leads to death by the age of twenty from respiratory or cardiac muscle failure. The illness, which primarily affects boys, occurs when a gene on the X chromosome fails to make the essential muscle protein dystrophin.

The use of gene therapy is to inject a smaller yet functional version of the gene - called a minigene - within the viral carrier.

Study Says Blacks With Muscular Dystrophy Die 10-12 Years Younger Than Whites
Research published in the Sept. 14 issue of Neurology, the medical journal of the American Academy of Neurology says that African Americans with muscular dystrophy die early

The researchers found that the immune response to the gene varied from patient to patient, perhaps in part because the patients harboured different amounts of "revertant" dystrophin fibers, fibers that have escaped the fate of their mutation. Further studies are needed, but this finding suggests that some patients may benefit from immunosuppression prior to receiving gene therapy.

One lesson from this study suggests that keeping a close eye on the immune-response profiles of patients could help to enhance the success of not just gene therapy, but also other therapies aimed at restoring dystrophin activity.

International Effort to Improve Muscular Dystrophy Treatment Led by Rochester
Physicians, physical therapists, and researchers at the University of Rochester Medical Center are launching a large international study aimed at improving the care of muscular dystrophy

The study has been published this week in the New England Journal of Medicine.

Source-ANI

Scientists Crack Muscular Dystrophy Gene Mystery
A critical advance in determining the cause of a common form of muscular dystrophy known as facioscapulohumeral dystrophy, or FSHD has been made by scientists.